92961-15-4

Basic information

• Product Name: 9-phenyl-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraene
• Synonyms: 9-phenyl-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraene;3-PHENYLIMIDAZO[1,2-A]PYRIDINE
• CAS NO: 92961-15-4
• Molecular Formula: C₁₃H₁₀N₂
• Molecular Weight: 194.23
• Mol File: 92961-15-4.mol
• Article Data: 27

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.13g/cm³
• Refractive Index: 1.638
• CAS DataBase Reference: 9-phenyl-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraene(CAS DataBase Reference)
• NIST Chemistry Reference: 9-phenyl-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraene(92961-15-4)
• EPA Substance Registry System: 9-phenyl-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraene(92961-15-4)

Safety Data

• Hazardous Substances Data: 92961-15-4(Hazardous Substances Data)

Usage

General Description

9-phenyl-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraene is a chemical compound with the molecular formula C15H14N2. It is a bicyclic compound with a phenyl group attached to a diazabicyclo nonaene backbone. 9-phenyl-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraene has potential applications in the field of organic chemistry and drug development due to its unique structure and reactivity. It may be used as a building block for the synthesis of complex organic molecules or as a precursor for the development of new pharmaceutical compounds. However, further research and testing are needed to fully understand and exploit the potential of 9-phenyl-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraene in various applications.

InChI:InChI=1/C13H10N2/c1-2-6-11(7-3-1)12-10-14-13-8-4-5-9-15(12)13/h1-10H

Upstream product

• 307503-19-1 3-iodo-imidazo[1,2-a]pyridine 
• 98-80-6 phenylboronic acid 
• 504-29-0 2-aminopyridine 
• 5153-67-3 nitrostyrene 
• 274-76-0 imidazo[1,2-a]pyridine 
• 66003-76-7 Diphenyliodonium triflate 
• 1483-72-3 diphenyliodonium chloride 
• 59-88-1 phenylhydrazine hydrochloride 
• 536-74-3 phenylacetylene 
• 108-90-7 chlorobenzene 
• 6200-60-8 imidazo[1,2-a]pyridine-3-carboxylic acid 
• 71-43-2 benzene 
• 108-86-1 bromobenzene 
• 79069-32-2 phenyl(phenylethynyl)iodonium tosylate 

Downstream Products

• 1609180-34-8 C₂₁H₁₈N₃O⁽¹⁺⁾*Cl^(1-) 

Relevant articles and documents

Cobalt-Catalyzed Direct Arylation of Imidazo[1,2-a]pyridine with Aryl Iodides

The Co(II)Cl2·6H2O catalyzed C–H activation/direct arylation of imidazo[1,2-a]pyridine with aryl/heteroaryl iodide is reported. The cost effective, ligand and additive free protocol using KOAc successfully afforded 3-arylimidazo[1,2-

Facile synthesis of 3-substituted imidazo[1,2-: A] pyridines through formimidamide chemistry

A facile entry to 3-aryl/alkenyl/alkynyl substituted imidazo[1,2-a]pyridines (3a-p, 6a-d & 9a-9e) has been developed from readily available benzyl/allyl/propargyl halides and 2-amino pyridines as substrates via formimidamide chemistry that is devoid of caustic or expensive reagents, such as transition metal complexes. Quantum chemical calculations performed to understand the underlying mechanism of the transformation revealed a preference for intramolecular Mannich-type addition over pericyclic 1,5-electrocyclization for the systems reported herein that enable a Baldwin allowed 5-exo-trig cyclization instead of a formally anti-Baldwin 5-endo-trig process.

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

The use of covalent irreversible binding inhibitors is an established concept for drug development. Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed. Herein, we report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia. A virtual screening library was designed to target the highly conserved Cys828 residue preceding the DFG motif by modification of reported reversible inhibitors with chemically reactive groups. Prospective covalent docking allowed the identification of two lead series, resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible inhibitors compared to the corresponding reversible scaffolds. Lead compound 4b (BSc5371) displays superior cytotoxicity in FLT3-dependent cell lines to compounds in recent clinical trials and overcomes drug-resistant mutations.